Acadia Pharmaceuticals (ACAD) Income from Continuing Operations (2010 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Income from Continuing Operations of 3681000.0 for Q1 2026, down 80.63% year-over-year from 19008000.0 in Q1 2025, and down 92.05% quarter-over-quarter from 46323000.0 in Q4 2025.
Powered by 
Analysis
Acadia Pharmaceuticals (ACAD) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 3681000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 80.63% year-over-year to 3681000.0; the TTM figure through Mar 2026 stood at 148438000.0 (down 41.69% YoY), while the FY2025 annual figure was 163723000.0, down 35.06% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 3681000.0, down from 46323000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 169415000.0 in Q4 2024, with the low at 113056000.0 in Q1 2022.
- The 5-year median for Income from Continuing Operations is 16600000.0 (2024), against an average of 8379882.35.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations plunged 139.62% in 2023, then soared 2897.22% in 2024.
- Acadia Pharmaceuticals' Income from Continuing Operations stood at 41644000.0 in 2022, then jumped by 209.77% to 45714000.0 in 2023, then soared by 270.6% to 169415000.0 in 2024, then tumbled by 72.66% to 46323000.0 in 2025, then slumped by 92.05% to 3681000.0 in 2026.
- Business Quant data shows ACAD's Income from Continuing Operations at 3681000.0 in Q1 2026, 46323000.0 in Q4 2025, and 71779000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Acadia Pharmaceuticals | 4.82 Bn | 3.86 Bn | 279.64 Mn | 31.50 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 31.50 Mn |
| Mar 31, 2026 | 3.66 Mn |
| Dec 31, 2025 | 273.55 Mn |
| Sep 30, 2025 | 71.80 Mn |
| Jun 30, 2025 | 26.67 Mn |
| Mar 31, 2025 | 19.00 Mn |
| Dec 31, 2024 | 121.18 Mn |
| Sep 30, 2024 | 32.77 Mn |
| Jun 30, 2024 | 33.40 Mn |
| Mar 31, 2024 | 16.56 Mn |
| Dec 31, 2023 | 66.77 Mn |
| Sep 30, 2023 | -65.18 Mn |
| Jun 30, 2023 | 1.11 Mn |
| Mar 31, 2023 | -43.02 Mn |
| Dec 31, 2022 | 5.68 Mn |
| Sep 30, 2022 | -27.22 Mn |
| Jun 30, 2022 | -34.04 Mn |
| Mar 31, 2022 | -113.10 Mn |
| Dec 31, 2021 | -7.56 Mn |
| Sep 30, 2021 | -14.46 Mn |